Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections.
The incidence of recurrent and refractory Clostridium difficile (rCDI) is increasing.1 Cirrhotic patients are at increased risk of CDI as a result of frequent hospitalizations, prophylactic antibiotics, proton pump inhibitor use, and comorbidities.2 In addition, cirrhotic patients with CDI have a higher mortality rate, longer length of stay, and a higher cost compared with noncirrhotic patients.3.